{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:41:25Z","timestamp":1787496085336,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["molpharm.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Pharmacology"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1124\/mol.107.036970","type":"journal-article","created":{"date-parts":[[2007,7,10]],"date-time":"2007-07-10T22:26:41Z","timestamp":1184106401000},"page":"1003-1014","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["A Mouse Model for Studying the Interaction of Bisdioxopiperazines with Topoisomerase II\u03b1 in Vivo"],"prefix":"10.1016","volume":"72","author":[{"given":"Morten","family":"Grauslund","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemette Vinding","family":"Thougaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"F\u00fcchtbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth Francis","family":"Hofland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Hansen","family":"Hjorth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter B.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxwell","family":"Sehested","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernst-Martin","family":"F\u00fcchtbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars H.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/mol.107.036970_REF1","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1046\/j.1365-2443.2003.00643.x","article-title":"Enforced cytokinesis without complete nuclear division in embryonic cells depleting the activity of DNA topoisomerase IIalpha","volume":"8","author":"Akimitsu","year":"2003","journal-title":"Genes Cells"},{"key":"10.1124\/mol.107.036970_REF2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/(SICI)1521-1878(199803)20:3<215::AID-BIES5>3.0.CO;2-Q","article-title":"Eukaryotic DNA topoisomerase II beta","volume":"20","author":"Austin","year":"1998","journal-title":"Bioessays"},{"key":"10.1124\/mol.107.036970_REF3","doi-asserted-by":"crossref","first-page":"27893","DOI":"10.1074\/jbc.M102544200","article-title":"The ATPase reaction cycle of yeast DNA topoisomerase II. Slow rates of ATP resynthesis and Pi release","volume":"276","author":"Baird","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.107.036970_REF4","doi-asserted-by":"crossref","first-page":"13685","DOI":"10.1073\/pnas.96.24.13685","article-title":"Topoisomerase II drives DNA transport by hydrolyzing one ATP","volume":"96","author":"Baird","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1124\/mol.107.036970_REF5","first-page":"127","article-title":"Limited activity of ICRF-159 in advanced acute leukemia","volume":"63","author":"Bakowski","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"10.1124\/mol.107.036970_REF6","doi-asserted-by":"crossref","first-page":"10629","DOI":"10.1073\/pnas.1832879100","article-title":"Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187","volume":"100","author":"Classen","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1124\/mol.107.036970_REF7","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2165\/00003495-200565070-00008","article-title":"Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy","volume":"65","author":"Cvetkovi\u0107","year":"2005","journal-title":"Drugs"},{"key":"10.1124\/mol.107.036970_REF8","doi-asserted-by":"crossref","first-page":"18753","DOI":"10.1074\/jbc.274.26.18753","article-title":"Evidence for repressional role of an inverted CCAAT box in cell cycle-dependent transcription of the human DNA topoisomerase II\u03b1 gene","volume":"274","author":"Falck","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.107.036970_REF9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0027-5107(03)00135-0","article-title":"DNA strand breaks induced by the anti-topoisomerase II bis-dioxopiperazine ICRF-193","volume":"530","author":"Hajji","year":"2003","journal-title":"Mutat Res"},{"key":"10.1124\/mol.107.036970_REF10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/0929867305666220314194045","article-title":"Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines","volume":"5","author":"Hasinoff","year":"1998","journal-title":"Curr Med Chem"},{"key":"10.1124\/mol.107.036970_REF11","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/0006-2952(95)00218-O","article-title":"A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane)","volume":"50","author":"Hasinoff","year":"1995","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/mol.107.036970_REF12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1385\/CT:3:2:89","article-title":"Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria","volume":"3","author":"Hasinoff","year":"2003","journal-title":"Cardiovasc Toxicol"},{"key":"10.1124\/mol.107.036970_REF13","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1124\/mol.64.3.670","article-title":"The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity","volume":"64","author":"Hasinoff","year":"2003","journal-title":"Mol Pharmacol"},{"key":"10.1124\/mol.107.036970_REF14","doi-asserted-by":"crossref","first-page":"6722","DOI":"10.1158\/1078-0432.CCR-05-0698","article-title":"Combining etoposide and dexrazoxane synergizes with radiotherapy and improves survival in mice with central nervous system tumors","volume":"11","author":"Hofland","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1124\/mol.107.036970_REF15","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1158\/1078-0432.CCR-04-2343","article-title":"Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin","volume":"11","author":"Hofland","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1124\/mol.107.036970_REF16","first-page":"1367","article-title":"Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide","volume":"4","author":"Holm","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1124\/mol.107.036970_REF17","doi-asserted-by":"crossref","first-page":"44488","DOI":"10.1074\/jbc.M104383200","article-title":"Topoisomerase II poisoning by ICRF-193","volume":"276","author":"Huang","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.107.036970_REF18","first-page":"2299","article-title":"DNA Topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae","volume":"55","author":"Ishida","year":"1995","journal-title":"Cancer Res"},{"key":"10.1124\/mol.107.036970_REF19","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1074\/jbc.275.3.2137","article-title":"A novel mechanism of cell killing by anti-topoisomerase II bisdioxopiperazines","volume":"275","author":"Jensen","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.107.036970_REF20","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S0026-895X(24)12220-1","article-title":"Maleimide is a potent inhibitor of topoisomerase II in vitro and in vivo: a new mode of catalytic inhibition","volume":"61","author":"Jensen","year":"2002","journal-title":"Mol Pharmacol"},{"key":"10.1124\/mol.107.036970_REF21","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0014-5793(00)01934-7","article-title":"N-terminal and core-domain random mutations in human topoisomerase II alpha conferring bisdioxopiperazine resistance","volume":"480","author":"Jensen","year":"2000","journal-title":"FEBS Lett"},{"key":"10.1124\/mol.107.036970_REF22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0304-3835(01)00447-5","article-title":"Decreased topoisomerase IIalpha expression confers increased resistance to ICRF-193 as well as VP-16 in mouse embryonic stem cells","volume":"166","author":"Kobayashi","year":"2001","journal-title":"Cancer Lett"},{"key":"10.1124\/mol.107.036970_REF23","first-page":"3680","article-title":"Treatment of anthracycline extravasation with dexrazoxane","volume":"6","author":"Langer","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1124\/mol.107.036970_REF24","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1074\/jbc.275.4.2613","article-title":"Steady-state and rapid kinetic analysis of topoisomerase II trapped as the closed-clamp intermediate by ICRF-193","volume":"275","author":"Morris","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.107.036970_REF25","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/annonc\/mdl413","article-title":"Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies","volume":"18","author":"Mouridsen","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1124\/mol.107.036970_REF26","doi-asserted-by":"crossref","first-page":"28100","DOI":"10.1074\/jbc.M402119200","article-title":"Dissecting the cell-killing mechanism of the topoisomerase II-targeting drug ICRF-193","volume":"279","author":"Oestergaard","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.107.036970_REF27","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/0076-6879(93)25054-6","article-title":"Gene targeting in embryonic stem cells","volume":"225","author":"Ram\u00edrez-Solis","year":"1993","journal-title":"Methods Enzymol"},{"key":"10.1124\/mol.107.036970_REF28","doi-asserted-by":"crossref","first-page":"9749","DOI":"10.1021\/bi034557d","article-title":"Analysis of bisdioxopiperazine dexrazoxane binding to human DNA topoisomerase II alpha: decreased binding as a mechanism of drug resistance","volume":"42","author":"Renodon-Corni\u00e8re","year":"2003","journal-title":"Biochemistry"},{"key":"10.1124\/mol.107.036970_REF29","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1073\/pnas.91.5.1781","article-title":"Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp","volume":"91","author":"Roca","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1124\/mol.107.036970_REF30","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/0092-8674(94)90222-4","article-title":"DNA transport by a type II DNA topoisomerase: evidence in favor of a two-gate mechanism","volume":"77","author":"Roca","year":"1994","journal-title":"Cell"},{"key":"10.1124\/mol.107.036970_REF31","first-page":"1460","article-title":"Chinese hamster ovary cells resistant to the topoisomerase ii catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines","volume":"58","author":"Sehested","year":"1998","journal-title":"Cancer Res"},{"key":"10.1124\/mol.107.036970_REF32","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.bbrc.2005.06.177","article-title":"Separation of bisdioxopiperazine- and vanadate resistance in topoisomerase II","volume":"334","author":"Sorensen","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/mol.107.036970_REF33","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1101\/gad.7.11.2071","article-title":"Perinatal lethality and defects in hindbrain development in mice homozygous for a targeted mutation of the zinc finger gene Krox20","volume":"7","author":"Swiatek","year":"1993","journal-title":"Genes Dev"},{"key":"10.1124\/mol.107.036970_REF34","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s002800050828","article-title":"Yeast cells expressing differential levels of human or yeast DNA topoisomerase II: a potent tool for identification and characterization of topoisomerase II-targeting antitumour agents","volume":"42","author":"van Hille","year":"1998","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/mol.107.036970_REF35","first-page":"249","article-title":"Phase I study of ICRF-187 using a daily for 3 days schedule","volume":"65","author":"Von Hoff","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"10.1124\/mol.107.036970_REF36","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/nrm831","article-title":"Cellular roles of DNA topoisomerases: a molecular perspective","volume":"3","author":"Wang","year":"2002","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1124\/mol.107.036970_REF37","first-page":"3442","article-title":"Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform","volume":"59","author":"Wessel","year":"1999","journal-title":"Cancer Res"},{"key":"10.1124\/mol.107.036970_REF38","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0014-5793(02)02805-3","article-title":"Human small cell lung cancer NYH cells resistant to the bisdioxopiperazine ICRF-187 exhibit a functional dominant Tyr165Ser mutation in the Walker A ATP binding site of topoisomerase II alpha","volume":"520","author":"Wessel","year":"2002","journal-title":"FEBS Lett"},{"key":"10.1124\/mol.107.036970_REF39","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1073\/pnas.0736401100","article-title":"The topoisomerase II\u03b2 circular clamp arrests transcription and signals a 26S proteasome pathway","volume":"100","author":"Xiao","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1124\/mol.107.036970_REF40","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1126\/science.287.5450.131","article-title":"DNA topoisomerase IIbeta and neural development","volume":"287","author":"Yang","year":"2000","journal-title":"Science"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24046029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24046029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/mol.107.036970","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T04:52:03Z","timestamp":1739940723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026895X24046029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["S0026895X24046029"],"URL":"https:\/\/doi.org\/10.1124\/mol.107.036970","relation":{},"ISSN":["0026-895X"],"issn-type":[{"value":"0026-895X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Mouse Model for Studying the Interaction of Bisdioxopiperazines with Topoisomerase II\u03b1 in Vivo","name":"articletitle","label":"Article Title"},{"value":"Molecular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/mol.107.036970","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2007 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}